Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.

Conference call to discuss new data presented for duvakitug (Anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

Aerosol Delivery Devices Market Research Report In 2019, the aerosol delivery devices market is projected to reach $46.73 billion by 2027, ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Appellate courts issued a variety of notable intellectual property (IP) cases in 2024, including cases touching on Orange Book ...

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA). And retail traders should know. We noticed this today when the trades showed up on ...

Axsome Therapeutics shares were up 14% in premarket trading after reaching a settlement with Teva Pharmaceuticals. Shares were trading around $120.01. The stock is up 8.3% over the last year.

In this study, we evaluated the efficacy and safety of budesonide/formoterol (160/4.5 µg dry powder via Spiromax, TEVA, corresponding to 200/6 ... ‘fixed-dose FSC’) one inhalation twice daily plus ...

Teva Pharmaceutical Industries Limited has a 12-month low of $11.83 and a 12-month high of $22.80. The stock has a market capitalization of $19.07 billion, a PE ratio of -11.61, a price-to ...